Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss is a frequent long-term effect of COVID-19, and oral minoxidil is the most common effective treatment.

Early high-dose steroid treatment helps prolong disease-free periods in severe alopecia areata.

Alopecia Areata severely impacts mental health, causing anxiety and depression, affecting quality of life.

A substance called miR-1246 may help treat severe hair loss by reducing certain immune cell activities.

Having asthma, atopic dermatitis, or Hashimoto's thyroiditis increases the risk of severe and long-lasting alopecia areata.

More severe alopecia areata can lower quality of life.

New treatments for severe hair loss often fail, but some patients see hair regrowth with specific therapies, and treatment should be tailored to the individual's situation.

Current treatments for severe alopecia areata are unsatisfactory, highlighting the need for better options.

Baricitinib shows promise for severe alopecia areata but isn't a cure and has side effects.

Botox injections may be a safe and effective way to treat severe, itchy skin disease when other treatments fail.

Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.

Certain immune cells contribute to severe hair loss in chronic alopecia areata, with Th17 cells possibly having a bigger impact than cytotoxic T cells.

Azathioprine may help treat severe alopecia areata, but more research is needed.

AA patients with comorbid conditions face more severe hair loss and need specific treatments.

Higher IL-17A levels indicate more severe alopecia areata.

Tofacitinib helped a young woman's severe hair loss and arthritis but not her plaque psoriasis.

Autoimmune and metabolic issues are linked, and treating one may worsen another.

A 14-year-old girl with severe hair loss regrew her hair using upadacitinib.

Higher antigliadin antibodies are linked to more severe alopecia areata, suggesting screening for celiac disease in these patients.

New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.

Older age at onset of alopecia areata leads to less severe and shorter episodes, with most patients experiencing significant hair regrowth.

Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.

Blocking IL-12/IL-23p40 helped reverse severe hair loss in patients.

Abrocitinib effectively treated severe atopic dermatitis and mild alopecia areata in a 12-year-old boy after dupilumab failed.

Genetic variations affecting skin structure play a key role in severe acne.

PRP is a promising and safe treatment for early to moderate knee osteoarthritis but needs standardized protocols.

Tofacitinib may help regrow hair in severe alopecia areata, but results differ greatly between people.

Upadacitinib is effective and safe for treating severe Alopecia Areata in adolescents.

Baricitinib helps improve hair growth in severe alopecia, with better results in less severe cases and higher doses working faster.

People with alopecia areata often have lower vitamin D levels, which are linked to more severe and longer-lasting hair loss, but vitamin D receptor levels in the skin don't show the same pattern and don't predict treatment success.